Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?

DOI	Resolve DOI: https://doi.org/10.1080/14760584.2022.2011226
Author	Search for: Chen, Wangxue¹ORCID identifier: https://orcid.org/0000-0003-0958-7728
Affiliation	National Research Council of Canada. Human Health Therapeutics
Funder	Search for: National Research Council Canada
Format	Text, Article
Subject	antimicrobial Resistance (AMR); mRNA vaccine; vaccine; alternatives to antibiotics; bacterial infection
Abstract	Antimicrobial resistance (AMR) has emerged as a major global public health catastrophe. Annual global deaths from AMR pathogen infections have been estimated to be ~700,000 and could reach 10 million by 2050, exceeding those due to cancer. In addition, AMR could result in up to 24 million people into extreme poverty by 2030 if no action is taken. The COVID-19 pandemic further exacerbates the AMR crisis because of the increased use of antibiotics for secondary bacterial infections and the delayed global action against AMR. As such, AMR has been recognized as a ‘silent’ or ‘the next’ pandemic by medical professions and public health experts.
Publication date	2021-12-03
Publisher	Taylor and Francis Group
In	Expert Review of Vaccines 21, no. 2 (3 December 2021): 155–157.
Language	English
Peer reviewed	Yes
Export citation	Export as RIS
Report a correction	Report a correction (opens in a new tab)
Record identifier	de2a8f1e-fa90-4dfa-8d08-bca57a020b79
Record created	2024-02-19
Record modified	2024-02-19